Companies › Xentria
1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Immunology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| XTMAB-16 | – | Phase 2 | Pulmonary Sarcoidosis | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06169397 | XTMAB-16 | Phase 2 | Pulmonary Sarcoidosis | Immunology | Oct 2026 |
| NCT05890729 | XTMAB-16 | Phase 1 | Pulmonary Sarcoidosis | Immunology | Oct 2026 |
No annotated target.
–
Restem Cellcolabs Clinical SPV EHL Bio Nature Cell Throne Biotechnologies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.